Información:
Error:
ID
34426
Descripción
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations; ODM derived from: https://clinicaltrials.gov/show/NCT01287754
Link
https://clinicaltrials.gov/show/NCT01287754
Palabras clave
Versiones (1)
- 17/1/19 17/1/19 -
Titular de derechos de autor
GSK group of companies
Subido en
17 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Non-Small Cell Lung Cancer NCT01287754
Eligibility Non-Small Cell Lung Cancer NCT01287754
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer NCT01287754
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
adult patients, >/=18 years of age
boolean
ID.2
Item
locally advanced or metastatic (stage iii/iv) non-small cell lung cancer with egfr mutations
boolean
ID.3
Item
measurable disease according to recist criteria
boolean
ID.4
Item
ecog performance status 0-2
boolean
ID.5
Item
adequate haematological, renal and liver function
boolean
ID.6
Item
previous chemotherapy or therapy against egfr for metastatic disease
boolean
ID.7
Item
history of another malignancy, except for in situ carcinoma of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis
boolean
ID.8
Item
symptomatic cerebral metastases
boolean
ID.9
Item
pre-existing parenchymal lung disease such as pulmonary fibrosis
boolean
ID.10
Item
concomitant use of coumarins
boolean